1188 related articles for article (PubMed ID: 28776423)
1. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
2. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.
Patel SA; Minn AJ
Immunity; 2018 Mar; 48(3):417-433. PubMed ID: 29562193
[TBL] [Abstract][Full Text] [Related]
3. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Maxwell R; Jackson CM; Lim M
Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
[TBL] [Abstract][Full Text] [Related]
4. The importance for immunoregulation for long-term cancer control.
Fusi A; Dalgleish A
Future Oncol; 2017 Aug; 13(18):1619-1632. PubMed ID: 28776411
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors: The linchpins of modern immunotherapy.
Wilky BA
Immunol Rev; 2019 Jul; 290(1):6-23. PubMed ID: 31355494
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
Duan J; Wang Y; Jiao S
Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
[TBL] [Abstract][Full Text] [Related]
7. Challenges faced when identifying patients for combination immunotherapy.
Ernstoff MS; Gandhi S; Pandey M; Puzanov I; Grivas P; Montero A; Velcheti V; Turk MJ; Diaz-Montero CM; Lewis LD; Morrison C
Future Oncol; 2017 Aug; 13(18):1607-1618. PubMed ID: 28835114
[TBL] [Abstract][Full Text] [Related]
8. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
9. Novel Immunotherapy Combinations.
Bashir B; Wilson MA
Curr Oncol Rep; 2019 Nov; 21(11):96. PubMed ID: 31696332
[TBL] [Abstract][Full Text] [Related]
10. Recent progress in therapeutic antibodies for cancer immunotherapy.
Lee A; Sun S; Sandler A; Hoang T
Curr Opin Chem Biol; 2018 Jun; 44():56-65. PubMed ID: 29885949
[TBL] [Abstract][Full Text] [Related]
11. Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.
Yan Y; Kumar AB; Finnes H; Markovic SN; Park S; Dronca RS; Dong H
Front Immunol; 2018; 9():1739. PubMed ID: 30100909
[TBL] [Abstract][Full Text] [Related]
12. Current status of immunotherapy for gastrointestinal stromal tumor.
Tan Y; Trent JC; Wilky BA; Kerr DA; Rosenberg AE
Cancer Gene Ther; 2017 Mar; 24(3):130-133. PubMed ID: 28186088
[TBL] [Abstract][Full Text] [Related]
13. Acquired resistance to cancer immunotherapy.
Draghi A; Chamberlain CA; Furness A; Donia M
Semin Immunopathol; 2019 Jan; 41(1):31-40. PubMed ID: 29968044
[TBL] [Abstract][Full Text] [Related]
14. Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer.
Schmidt EV
Semin Immunopathol; 2019 Jan; 41(1):21-30. PubMed ID: 30374524
[TBL] [Abstract][Full Text] [Related]
15. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
Cavalcante L; Chowdhary A; Sosman JA; Chandra S
Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic viruses-immunotherapeutics on the rise.
Keller BA; Bell JC
J Mol Med (Berl); 2016 Sep; 94(9):979-91. PubMed ID: 27492706
[TBL] [Abstract][Full Text] [Related]
18. Cancer Immunotherapy in Older Patients.
Marrone KA; Forde PM
Cancer J; 2017; 23(4):219-222. PubMed ID: 28731944
[TBL] [Abstract][Full Text] [Related]
19. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint therapy in liver cancer.
Xu F; Jin T; Zhu Y; Dai C
J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
